Introduction: The 2018 European Society of Cardiology / European Society of Hypertension guidelines recommended the use of combination therapy, especially in the form of single‑pill combinations (SPCs), for treatment of hypertension.
Objectives: We assessed adherence to these recommendations after their publication and during the COVID‑19 pandemic in Poland.
Patients And Methods: The frequencies of using individual antihypertensive drug classes and their combinations were analyzed for the years 2019, 2020, and 2021 in all patients who filled at least 1 prescription for an antihypertensive drug, using information from a database covering all prescriptions filled in Poland.
Results: In the years 2019, 2020, and 2021, a total of 10 328 341, 9 478 949, and 9 637 595 patients, respectively, fulfilled the inclusion criteria. There was a continuous decrease in the rate of patients meeting the criteria for coprescribing 2 or more antihypertensive drugs in the consecutive years (59.3%, 49%, 45.6%, respectively, in 2019, 2020, and 2021; P <0.001). In 2019, 2020, and 2021, a combination of renin‑angiotensin system blockers, calcium channel blockers and / or diuretics was respectively used by 41.7%, 40.9%, and 42% of the patients taking 2 antihypertensive drugs (P <0.001), and by 15.2%, 17.2%, and 18.5% of the patients taking 3 antihypertensive drugs (P <0.001). There was an increase in the use of β‑blockers over the study period (62%, 62.8%, and 63.7%, respectively, in 2019, 2020, and 2021; P <0.001). Double SPCs were used by 28%, 28.7%, and 29.8% of the patients (P <0.001), and triple SPCs by 2.6%, 2.9%, and 3.4% of the patients (P <0.001), respectively, in 2019, 2020, and 2021.
Conclusions: During the COVID‑19 pandemic, a decrease in the frequency of combination treatments and an increase in the frequency of dual and triple SPC use were observed. Despite the slow increase in the frequency of prescribing the guideline‑recommended drug combinations, their use remains suboptimal.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.20452/pamw.16647 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Guidance for Prescribing Oral Antihypertensive Medications in the Emergency Department.
Curr Hypertens Rep
January 2025
Department of Emergency Medicine, Integrative Biosciences Center, Wayne State University, Detroit, MI, USA.
Purpose Of Review: To review the most current recommendations regarding assessment and treatment of asymptomatic hypertension treatment in the emergency department (ED) and to provide guidance for prescribing oral antihypertensive therapy for ED providers.
Recent Findings: There are varying management strategies for the treatment of asymptomatic hypertension in the ED likely due to a lack of direct guidelines for treatment. There is an increasing body of evidence for the safety of initiating therapy to treat chronic asymptomatic hypertension in the ED.
No genetic causal links detected between antihypertensive medications and skin cancer: insights from a trans-ancestry, drug-target mendelian randomization analysis.
Arch Dermatol Res
January 2025
Department of Ultrasound, Affiliated Hospital of Nantong University, Nantong, 226001, China.
[Hypertension : what's new in 2024].
Rev Med Suisse
January 2025
Service de néphrologie et d'hypertension, Centre hospitalier universitaire vaudois, 1005 Lausanne.
The major clinical studies in 2024 reviewed in this manuscript will focus on blood pressure measurement, the effect of coffee on the latter, its follow-up in the postpartum period, blood pressure targets for patients at high cardiovascular risk, particularly those with diabetes, and the late onset of primary aldosteronism after a negative initial confirmation test.
View Article and Find Full Text PDFBackground And Aims: Drug-drug interactions (DDIs) are a significant health issue that may adversely affect the health and well-being of patients. This study assesses and compares potential DDI (pDDI) patterns, severity, and associated risk factors in government and private hospitals in Dhaka, Bangladesh.
Methods: A total of 188 and 206 prescriptions were collected from various government and private hospitals' outdoor departments, respectively, by capturing pictures of the prescriptions.
Adrenomedullin 2 attenuates anxiety-like behaviors by increasing IGF-II in amygdala and re-establishing blood-brain barrier.
Transl Psychiatry
January 2025
Department of Neurosurgery, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
Anxiety disorder, a prevalent mental health issue, is one of the leading causes of disability worldwide. Damage to the blood-brain barrier (BBB) is implicated in anxiety, but its regulatory mechanisms remain unclear. Herein, we show that adrenomedullin 2 (ADM2), a novel angiogenic growth factor, alleviates autistic and anxiety-like behaviors in mice.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!